Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  An, She Juan ^a   Chen, Zhi Hong ^a   Su, Jian ^a   Zhang, Xu Chao ^a   Zhong, Wen Zhao ^a   Yang, Jin Ji ^a   Zhou, Qing ^a   Yang, Xue Ning ^a   Huang, Ling ^a   Guan, Ji Lin ^a   Nie, Qiang ^a   Yan, Hong Hong ^a   Mok, Tony S ^b   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRAF GENE; C MET GENE; CANCER PATIENT; EGFR GENE; EML4 ALK GENE; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GENETIC DIFFERENCE; GENETIC IDENTIFICATION; HISTOLOGY; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PIK3CA GENE; POLYMERASE CHAIN REACTION; PTEN GENE; SMOKING; STK11 GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84863104686     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040109     Document Type: Article

References (32)

1. Mitsudomi T, (2010) Advances in target therapy for lung cancer. Jpn J Clin Oncol 40: 101-106.
2. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, et al. (2010) Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 36: S21-29.
3. Sun Y, Ren Y, Fang Z, Li C, Fang R, et al. (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28: 4616-4620.
4. Youn A, Simon R, (2011) Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics 27: 175-181.
5. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, et al. (2011) Mutations in the DDR2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer. Cancer Discovery 1: 76-87.
6. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, et al. (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One 5: e14117.
7. Gao Y, Ge G, Ji H, (2011) LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell 2: 99-107.
8. Sanchez-Cespedes M, (2011) The role of LKB1 in lung cancer. Fam Cancer 10: 447-453.
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
10. Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, et al. (2010) Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 69: 110-115.
11. Shepherd FA, (2011) Molecular selection trumps clinical selection. J Clin Oncol 29: 2843-2844.
12. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, et al. (2011) Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 29: 3316-3321.
13. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, et al. (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247-253.
14. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, et al. (2010) Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 9: 188.
15. Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, et al. (2009) Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 15: 651-658.
16. O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, et al. (2011) Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 12: 795-805.
17. Zhou W, Christiani DC, (2011) East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer 30: 287-292.
18. Mao C, Qiu LX, Liao RY, Du FB, Ding H, et al. (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69: 272-278.
19. Thunnissen FB, Prinsen C, Hol B, Van der Drift M, Vesin A, et al. (2012) Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development. Lung Cancer 75(2): 156-160.
20. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, et al. (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29: 2046-2051.
21. Hata A, Katakami N, Fujita S, Kaji R, Imai Y, et al. (2010) Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 5: 1197-1200.
22. Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC, (2009) Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 6: 528-534.
23. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. (2011) Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29 (suppl): abstr CRA7506.
24. West H, Harpole D, Travis W, (2009) Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 136: 1112-1118.
25. Scagliotti GV, Longo M, Novello S, (2009) Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 21: 99-104.
26. Cadranel J, Zalcman G, Sequist L, (2011) Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. Eur Respir J 37: 183-193.
27. Vakiani E, Solit DB, (2011) KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 223: 219-229.
28. Pao W, Girard N, (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180.
29. Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, et al. (2006) Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133: 203-206.
30. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, et al. (2010) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17: 889-897.
31. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, et al. (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3: 13-17.
32. Sonobe M, Nakagawa M, Takenaka K, Katakura H, Adachi M, et al. (2007) Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol 95: 63-69.